David Carbone

David Carbone, MD, PhD

Physician

Make an Appointment

Overall Patient Satisfaction Rating

stars
4.9 out of 5
51
Reviews
2
Comments

Gender

Male

Biography


I am a medical oncologist and my 25-year career as an oncologist has been focused on creating cutting-edge treatments for patients with lung cancer. This is a disease with unacceptable outcomes, but there are many promising therapies today and on the horizon. I was named to the Castle Connolly list of “America's Top Doctors” from 2004-2018 and rated in the top 10 percent of physicians in the nation for patient satisfaction in 2016.

My research has been in the molecular biology of lung tumors, which includes understanding the genetic, proteomic and metabolic features of each patient’s cancer, and developing treatment and drugs that target specific tumor cells.

I’ve served as an investigator on multiple clinical trials, including the large phase III lung cancer trials, for the Eastern Cooperative Oncology Group (ECOG), one of the largest clinical cancer research organizations in the U.S. Additionally, I’ve authored more than 200 peer-reviewed publications, book chapters and articles. I have served on several National Cancer Institute (NCI) grant review panels and the NCI Board of Scientific Counselors.

In 2012, I came to Ohio State from Vanderbilt University to establish and direct the OSUCCC – James thoracic center. With our multidisciplinary team approach, we apply advanced molecular diagnostics and state-of-the-art therapeutics to provide personalized care every lung cancer patient. I also serve as a professor of internal medicine and hold the Barbara J. Bonner Chair in Lung Research. I currently serve as the President of the International Association for the Study of Lung Cancer (IASLC).

The collaborative spirit, team approach, dedicated patient care and enlightened leadership we enjoy at the OSUCCC – James all come together together to make this a great place to work – and a great place to receive treatment for cancer.

Education and Background

Education

Internal Medicine

Johns Hopkins University School of Medicine

Baltimore, MD

Residencies

Johns Hopkins Medical Center

Baltimore, MD

Fellowship

Medical Oncology

National Cancer Institute

Bethesda, MD

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine (Subspecialty: Medicine Oncology)

Academic Department

Department of Internal Medicine

Division of Medical Oncology


Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 12/20/2018, Dr. Carbone has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.

AstraZeneca

Bristol-Myers Squibb

EMD Serono, Inc.

Merck & Co., Inc.

Pfizer, Inc.

PRIME Continuing Medical Education, Inc.

AbbVie Inc.

Incyte Pharmaceuticals

Axion Life Sciences

Humana, Inc.

Merck Sharp & Dohme Corp

Roche Holding AG

Reviews

Patient Satisfaction Review

The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page

The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.

Overall Ratings (out of 51 reviews)
stars
4.9 out of 5
Kept you informed about your condition and treatment

4.9/ 5

Amount of time spent with you

4.9/ 5

Concern for your questions and issues

4.9/ 5

Skill and knowledge

4.9/ 5

Overall quality of care

4.9/ 5

Patient Comments (2 total comments)

stars
Reviewed: 4/20/2019

Excellent

stars
Reviewed: 3/11/2019

Outstanding skill & deep compassion.

Publications

The effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibition in non-small cell lung cancer.

Shukuya T, Yamada T, Koenig MJ, Xu J, Okimoto T, Li F, Amann JM, Carbone DP

J Thorac Oncol in press

2/27/2019

Co-Expression Analysis Reveals Mechanisms Underlying the Varied Roles of NOTCH1 in NSCLC.

Sinicropi-Yao SL, Amann JM, Lopez DLY, Cerciello F, Coombes KR, Carbone DP

J Thorac Oncol 14

2/1/2019

Related Videos

How Genetics Can Play a Role in Lung Cancer Risk
Immunotherapy Advances Changing Some Lung Cancer Treatments
Back to Find a Doctor Search

Make an Appointment

800-293-5066

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

OR

Please enter a keyword (i.e. Name, Location) or choose a Cancer Type

OR